Jackson, TENN. (PRWEB) June 07, 2013
The week of May 13, a team of doctors working together through the West Tennessee Heart & Vascular Center (WTHVC) at Jackson-Madison County General Hospital performed the first three transcatheter aortic valve replacements (TAVR) in Jackson.
Transcatheter valve replacements are for patients at high-risk for traditional aortic valve replacement. Prior to the approval of TAVR, heart patients that were not healthy enough to undergo open-heart surgery had no long-term options for extending their lives.
The multi-disciplinary TAVR team at WTHVC is made up of cardiologists, cardiothoracic surgeons, radiologists, and anesthesiologists from seven different practices in Jackson. This unprecedented collaboration is coordinated through WTHVC, which has appointed a Valve Clinic Coordinator.
The TAVR team includes:
Dr. Michael Bearb, Anesthesiologist, Cardiac Anesthesia Group
Dr. Greg Bruno, Radiologist, Jackson Radiology Associates
Dr. Jason Cherry, Cardiologist, The Jackson Clinic
Dr. James Crenshaw, Cardiologist, The Jackson Clinic
Dr. John Crocker, Radiologist, Jackson Radiology Associates
Dr. Arthur Grimball, Cardiothoracic Surgeon, WTHVC Cardiothoracic Surgery Center
Dr. Tommy Miller, Cardiologist, Mid-South Heart Center
Dr. Michael Osayamen, Cardiologist, The Jackson Clinic
Dr. Shahzad Shah, Cardiologist, The Jackson Clinic
Dr. Eric Sievers, Cardiothoracic Surgeon, WTHVC Cardiothoracic Surgery Center
Scott Sweat, RN, Valve Clinic Coordinator, WTHVC
Dr. Ronald Weiner, Cardiologist, Skyline Cardiovascular Institute
All three patients were released from Jackson-Madison County General Hospital within days of the procedure. TAVR is a significant breakthrough for patients facing heart disease. Minimally invasive procedures like TAVR allow for quicker recovery, with patients returning to normal activities soon afterwards.
The FDA approved TAVR in November 2011. The Jackson team of doctors working together with the West Tennessee Heart & Vascular Center at Jackson-Madison County General Hospital has undergone intensive training and preparation to bring this ground breaking procedure to Jackson.
Heart disease is the leading cause of death in the U.S. with more than five million Americans diagnosed with heart valve disease each year. Without valve replacement, approximately half of those with heart disease will not survive more than two years.
The new TAVR treatment option is one of many advanced procedures available at West Tennessee Heart & Vascular Center. WTHVC is the only hospital in West Tennessee outside of Memphis that performs open-heart surgery. The hospital has received the highest level of accreditation; Chest Pain Center with PCI Accreditation from the Society of Chest Pain Centers.
As a comprehensive center, WTHVC services extend from diagnostics, to treatment, to cardiac rehabilitation. Jackson-Madison County General Hospital treats more heart attack patients than any other hospital in Tennessee.
ADDITIONAL INFORMATION ABOUT THE TAVR PROCEDURE
WTHVC performed the transcatheter aortic valve replacements (TAVR) with the Edwards SAPIEN transcatheter heart valve for patients at high-risk for surgical aortic valve replacement (AVR). The Edwards SAPIEN Transcatheter Heart Valve is the only FDA-approved TAVR therapy in the U.S.
- The Edwards SAPIEN Transcatheter Heart Valve is FDA-approved for the treatment of both inoperable and high-risk patients with severe, symptomatic calcified native aortic valve stenosis in need of an aortic valve replacement.
- The Edwards SAPIEN Transcatheter Heart Valve delivered via a small cut in the leg, or the transfemoral procedure, was first approved in the U.S. in November 2011 by the FDA as a therapy for inoperable patients.
- This procedure enables the placement of a collapsible aortic heart valve into the body via a tube based delivery system that is inserted through either an incision in the leg and threaded up to the heart, or through an incision between the ribs and inserted through the narrow, bottom end of the heart called the apex.
- The Edwards SAPIEN valve is designed to replace a patient’s diseased native aortic valve without the need for open-chest surgery and without stopping the patient’s heart.
The TAVR procedure has now been approved in over 50 countries. Worldwide, more than 30,000 patients have been implanted with Edwards’ transcatheter valves by multi-disciplinary heart teams specially trained in this procedure.